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Background: The effects of atorvastatin on SDF-1α expression under acute myocardial infarction (AMI) are still
unclear. Therefore, our present study is to investigate the roles and mechanisms of atorvastatin treatment on
SDF-1α expression in rats with AMI.
Methods: Male Sprague–Dawley rats were underwent permanent coronary artery ligation and randomly assigned
into four groups as follow: blank control (B), atorvastatin (A), atorvastatin plus L-NAME (A+L-NAME), and atorvastatin
plus AMD3100 (A+AMD3100). Rats underwent similar procedure but without ligation were used as group sham
operated (S). Atorvastatin (10mg/Kg/d body weight) was administrated by gavage to rats in three atorvastatin
treated groups, and L-NAME (40mg/Kg/d body weight) or AMD3100 (5mg/Kg/d body weight) was given to group
A+L-NAME or A+AMD3100, respectively.
Results: Comparing with group B, NO production, SDF-1α and CXCR4 expression were significantly up-regulated in
three atorvastatin treated groups at the seventh day. However, the increments of SDF-1α and CXCR4 expression in
group A+L-NAME were reduced when NO production was inhibited by L-NAME. Anti-inflammatory and
anti-apoptotic effects of atorvastatin were offset either by decrease of SDF-1α and CXCR4 expression (by L-NAME)
or blockage of SDF-1α coupling with CXCR4 (by AMD3100). Expression of STAT3, a cardioprotective factor
mediating SDF-1α/CXCR4 axis induced cardiac protection, was up-regulated most significantly in group A. The
effects of atorvastatin therapy on cardiac function were also abrogated either when SDF-1α and CXCR4 expression
was diminished or the coupling of SDF-1α with CXCR4 was blocked.
Conclusion: SDF-1α upregulation by atorvastatin in rats with AMI was, at least partially, via the eNOS/NO
dependent pathway, and SDF-1α upregulation and SDF-1α coupling with CXCR4 conferred anti-inflammatory and
anti-apoptotic effects under AMI setting which we speculated that ultimately contributed to cardiac function
improvement.
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SDF-1α (stromal cell-derived factor-1alpha) is a small
cytokine belonging to the chemokine family that is
officially designated as Chemokine (C-X-C motif ) li-
gand 12 (CXCL12). CXCR4 is a receptor for the C-X-
C chemokine CXCL12/SDF-1 that transduces a signal
by increasing intracellular calcium ions levels. Ac-
cordingly, SDF-1α constitutively expresses in cardiac
tissues and correspondingly increases after acute myo-
cardial infarction (AMI) so as to conduct self-
protective process [1-3]. Through the coupling with
its cognate receptor CXCR4, SDF-1α exerts multiple
protective effects, as anti-apoptosis, pro-survival, car-
diac remodeling amelioration, endothelial progenitor
cells recruitment and neo-vascularization, to improve
cardiac function [4-7]. However, the natural physio-
logic reaction of transient and slight upregulation of
SDF-1α after AMI is far from sufficient to fully re-
store cardiac function [1,8,9]. Therefore, in animal
models of ischemic cardiac diseases, many genetically
manipulative strategies aiming to extending and en-
hancing SDF-1α expression have been intensively
investigated [9-11]. The outcomes are striking and
shed promising lights on SDF-1α potentially thera-
peutic efficacy on ischemic diseases. Notwithstanding,
those novel genetic approaches seem infeasible in
clinical practice at present time. Hence, it is war-
ranted and necessitated to investigate whether com-
monly used medications have potential to up-regulate
SDF-1α expression after AMI. To our knowledge,
there has been rare study to explore this kind of ef-
fect with commonly used medications. Previously, Xu
and colleagues reported that SDF-1α expression in is-
chemic brain could be up-regulated by simvastatin
[12], but the underlying mechanism had not been suf-
ficiently investigated. Recently, Feng and co-workers
reported that over-expression of endothelial nitric
oxide synthase (eNOS) in cardiac tissues could in-
crease SDF-1α expression in mice with ischemic-
reperfusion injury [13]. As is well known that
stabilization of eNOS mRNA and increase of nitric
oxide (NO) production are the main mechanisms by
which statins confer pleiotropic effects on cardiovas-
cular diseases [14,15]. Taken together, it is reasonable
to speculate that statins, the commonly used and ea-
sily available medication, may be the potential candi-
date used to enhance SDF-1α expression immediately
after ischemic insult. Furthermore, we hypothesized
that increase of SDF-1α might be, at least partially,
attributable to eNOS upregulation and NO production
by statins treatment, and the reciprocal coupling of
SDF-1α with CXCR4 might be another novel mecha-
nism by which statins confer its pleiotropic effects on
cardiovascular diseases.Methods
AMI production and atorvastatin administration
Healthy male Sprague–Dawley rats weighing 200-220g
were obtained from the Experimental Animal Center of
Sun Yat-sen University, Guangzhou, China. The study
was approved by the Ethic Committee of Sun Yat-sen
University. All animals received humane care in com-
pliance with the Guide for the Care and Use of Labora-
tory Animals of the Institute of Laboratory Animal
Resources, National Research Council.
Induction of AMI was performed as previously
described by permanent ligation of the left anterior des-
cending coronary artery [16]. And 36 survived rats were
randomly and evenly assigned into four groups as blank
control (B), atorvastatin (A), atorvastatin plus NG-Nitro-
L-arginine Methyl Ester (L-NAME) (group A+L-NAME),
and atorvastatin plus AMD3100 (group A+AMD3100).
Another 9 rats underwent similar procedure but without
coronary artery ligation were used as sham operated (S).
Atorvastatin (10mg/Kg/d body weight, kindly offered by
Pfizer Inc., solved in normal saline) was administrated by
gavage once daily in the morning to group A, group
A+L-NAME and group A+AMD3100, and same volume
of saline was given to group B and group S. Eight hours
later, L-NAME (40mg/Kg/d body weight, Sigma, St. Louis,
MO , N5751) was given by gavage to group A+L-
NAME, same volume saline was given to the other
groups, and AMD-3100 (5mg/Kg/d body weight,
Sigma, St. Louis, MO, A5602) was given to group A
+AMD3100 by subcutaneous injection, same volume
saline was subcutaneously injected to the other groups,
the administration was once daily also. The general
course was 7 days. One day after AMI, three rats from
each group were used for cardiac function analysis, and
then followed by heart excision for NO and SDF-1α
evaluation. Seven days later, the rest rats were used for
the following assessments after echocardiography was
performed for cardiac function evaluation.
Expression of eNOS /p-eNOS, STAT3 and CXCR4 in
myocardium by Western blot
Seven days after AMI, expression of eNOS, p-eNOS,
STAT3 and CXCR4 was detected by Western blot.
Briefly, protein was extracted from infarcted and peri-
infarcted regions of myocardium. Tissues were lysed
with 500 μL of lysis buffer (50 mM Tris–HCl, pH 7.5;
5 mM EDTA; 250 mM NaCl; and 0.1% Triton X-100)
containing 20μL (10mg/ml) of protease inhibitors Phe-
nylmethanesulfonyl Fluoride (PMSF). Concentration of
protein was measured by Bicinchoninic acid (BCA)
method. Twenty micrograms of protein was electropho-
resed on an 8% SDS-polyacrylamide gel and then trans-
ferred to a 0.22μm pore-sized Polyvinylidene Fluoride
(PVDF) membrane. After blocking with 0.1% Tween in
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temperature for 1h, membranes were incubated at 4°C
overnight with rabbit anti-rat eNOS, p-eNOS (Cell Sig-
naling Technology, Danvers, MA, #9586 and #9570,
1:1000), rabbit anti-rat STAT3 (Cell Signaling Techno-
logy, Danvers, MA, #4904, 1:1000), and rabbit anti-rat
CXCR4 (Santa Cruz, CA, sc-9046, 1:50). The mem-
branes were washed three times with TBS-T and incu-
bated with goat anti-rabbit IgG HRP-conjugated
secondary antibody (Cell Signaling Technology, Danvers,
MA, #7074, 1:3000) at room temperature for 1h. Inter-
ested protein was detected by chemiluminescence, and
optical density (OD) was measured in grey scale images
with Volume Contour method. GAPDH (Cell Signaling
Technology, Danvers, MA, #2118, 1:6000) was used as a
loading control. All the data were presented as relative
expression after normalized to GAPDH. All the mea-
surements were repeated for 3 times to figure out the
arithmetic average.
Evaluation of inflammatory cytokines and anti-apoptotic
and pro-apoptotic proteins by Western blot
After seven days of AMI, expression of inflammatory
cytokines (TGF-β, IL-1, IL-6, and TNF-α), pro-apoptotic
(Bax) and anti-apoptotic (Bcl-2 and p-Akt) signals were
detected by Western blot. Tissues were extracted from
infarcted and peri-infarcted regions of myocardium, and
then homogenized in 500 μL lysate (described aboved).
After electrophoresis, transmembrane, and blocking,
membrane was incubated at 4°C overnight with rabbit
anti-rat TGF-β (Cell Signaling Technology, Danvers,
MA, #3711, 1:1000), or IL-1, IL6 (Sigma, St. Louis, MO,
I5018, SAB4300383, 1:1000), or TNF-α (Cell Signaling
Technology, Danvers, MA, #3727, 1:1000), or Bax (Cell
Signaling Technology, Danvers, MA, #2772, 1:1000), or
Bcl-2 (Cell Signaling Technology, Danvers, MA, #2876,
1:1000) or p-Akt (Cell Signaling Technology, Danvers,
MA, #9275, 1:1000). The membranes were washed three
times with TBS-T and incubated with goat anti-rabbit
IgG HRP-conjugated secondary antibody (Cell Signaling
Technology, Danvers, MA, #7074, 1:3000) at room
temperature for 1h. The rest procedures were as
described above. All the measurements were repeated
for 3 times to figure out the arithmetic average.
Measurement of NO production in cardiac tissue
Total nitric oxide (NO) was evaluated by nitrite reduc-
tase method using Total Nitric Oxide Kit (Beyotime,
Haimen, China, S0023). All the procedures were per-
formed according to the manufacturer’s protocol. NO
productions in the first and seventh day of AMI were
evaluated. Tissue from the infarcted and peri-infarcted
regions of myocardium was homogenized in lysate with
25 mmol/L Tris, 1% Triton X-100, 0.5 mmol/L EDTA,150 mmol/L NaCl, 10 mmol/L NaF and a protease in-
hibitor PMSF 20μL (10mg/ml). After quantified by the
Bicinchoninic acid (BCA) assay, protein concentration
was adjusted to 10mg/ml. Potassium Nitrite (KNO2)
supplied within the Total Nitric Oxide Kit was used to
figure out standard curve. Optical density of each sam-
ple was detected by Enzyme-labeling measuring instru-
ment at a wavelength of 550nm, and concentration was
figured out on the standard curve. All the measure-
ments were repeated for 3 times to figure out the arith-
metic average.
ELISA assay for SDF-1α expression
Quantitative immunoassay was used for evaluating ex-
pression of SDF-1α in the first and seventh day after
AMI. Procedures were performed according to the man-
ufacturer’s protocol (R&D Systems, Minneapolis, MN).
Tissues from the infarcted and peri-infarcted regions of
myocardium were homogenized in lysate (as described
above). Protein concentration was adjusted to 10mg/ml.
Recombinant murine SDF-1α supplied within the kit
was used to figure out standard curve. Optical density of
each sample was detected by Enzyme-labeling measuring
instrument at a wavelength of 460nm, and the concen-
tration was figured out on the standard curve. All the
measurements were repeated for 3 times to figure out
the arithmetic average.
Hematoxylin-eosin staining and TUNEL detection
Cardiac tissues were embedded in 4μm paraffin sections
for histological and TdT-mediated dUTP nick-end label-
ing (TUNEL) detections. The degree of inflammatory
cells infiltration was evaluated by counting the number
of inflammatory cells in 10 randomly peri-infarcted areas
of each group at 200× magnification. Apoptotic index in
peri-infarct areas was evaluated by TUNEL (Roche,
Germany) 7 days after AMI. Procedures were performed
according to the manufacture’s instruction. Slides were
examined under a light microscope at 400× magnifica-
tion. Normal cardiomyocytes nuclei were stained as
blue while apoptotic ones were brown. Negative control
(NC) was stained with removal of terminal transferase.
The apoptotic index was calculated as TUNEL-positive
nucleus divided by total number of nucleus in each
field. Cells were counted at 10 random fields.
Cardiac function analysis with echocardiography
Parameters of cardiac function were evaluated before,
1 and 7 days after AMI. Left ventricular ejection frac-
tion (LVEF), fractional shortening (FS), left ventricular
end-systolic and end-diastolic volume (LVVs and
LVVd), heart rate (HR) and cardiac output (CO) were
evaluated in each group with an echocardiography sys-
tem (ATL-HDI500) equipped with a 10-MHz image
Figure 1 Panel (a), 7 days after AMI, eNOS was significantly increased in AMI groups when compared with group S, and the three
atorvastatin groups presented higher augmentation of eNOS. (S: 0.16±0.06, B: 0.53±0.11*, A: 0.98±0.18*#, AL: 1.03±0.16*#, AA: 0.95±0.15*#).
Similar result was observed in p-eNOS (S: 0.28±0.09, B: 0.56±0.13*, A: 0.89±0.20*#, AL: 0.91±0.83*#, AA: 0.83±0.16*#). (*: P<0.01 vs. group S, #:
P<0.01 vs. group B). As shown in panel (b) and (c), one day after AMI, AMI groups showed slightly higher level of NO production than group S
(S: 5.11±0.78, B: 5.56±0.66, A: 5.71±0.81, AL: 5.62±0.86, AA: 5.69±0.68, P=0.042 vs. group S). Similar trend was also observed in SDF-1α expression
(S: 7.12±0.57, B: 7.43±0.71, A: 7.37±0.66, AL: 7.51±0.62, AA: 7.47±0.73, P=0.044 vs. group S). Seven days after AMI, NO production was significantly
increased in three atorvastatin groups when compared with group B, while increment in group A+L-NAME was abrogated (S: 5.12±1.10, B: 5.36±0.98,
A: 9.89±0.86*#, AL: 7.01±1.03*#$, AA: 9.60±0.92*#). SDF-1α expression in three atorvastatin groups was also increased when compared with group B,
while the increment was reduced in group A+L-NAME after NO production was diminished by L-NAME (S: 6.91±0.67, B: 7.22±0.89, A: 12.73±1.23*#,
AL:10.51±0.95*#$, AA:11.59±1.16*#). (*: P<0.01 vs. group S, #: P<0.01 vs. group B, $: P<0.01 vs. group A and group AA). As shown in panel (d), 7 days
after AMI, CXCR4 was significantly increased in all three atorvastatin groups. (S: 0.19±0.08, B: 0.23±0.13, A: 0.79±0.21*#, AL: 0.52±0.17*#$, AA: 0.73±0.19*#).
Similar result was observed in STAT3 (S: 0.13±0.09, B: 0.20±0.10, A: 0.62±0.15*#, AL: 0.37±0.11*#$, AA: 0.33±0.13*#$). (*: P<0.01 vs. group S, #: P<0.01 vs.
group B, $: P<0.01 vs. group A) All the measurements were repeated for 3 times to figure out arithmetic average. S=Sham operated group; B=Blank
control group; A=Atorvastatin group; AL=Atorvastatin+L-NAME group; AA=Atorvastatin+AMD3100 group.
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Figure 2 (See legend on next page.)
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following formula: CO=LVVd-LVVs. All procedures
were performed by an experienced investigator who
was blinded to the groups. All the measurements were
repeated for 3 times.Statistical analysis
All continuous variables were expressed as mean±SD,
and analyses were performed with SPSS software,
version 16.0 (SPSS Science, Chicago, IL, USA). Sta-
tistical significance among different groups was
(See figure on previous page.)
Figure 2 Panel (a) and (b), 7 days after AMI, inflammatory cytokines expression atorvastatin treated group was significantly diminished
when compared with group B. Meanwhile, the number of inflammatory cells infiltration was also concomitantly reduced in atorvastatin treated
groups. And the effects of anti-inflammation by atorvastatin treatment were abrogated by L-NAME or AMD3100, as demonstrated by that both
the expressions of inflammatory cytokines and the number of inflammatory cells were significantly reduced in group A than group A+L-NAME
and group A+AMD3100. TGF-β (S: 0.18±0.06, B: 0.89±0.15*, A: 0.26±0.09*#, AL: 0.82±0.10*$, AA: 0.87±0.16*$), IL-6 (S: 0.40±0.08, B: 1.44±0.20*, A:
0.58±0.11*#, AL: 1.32±0.18*$, AA: 1.26±0.21*$), IL-1 (S: 0.56±0.13, B: 1.46±0.23*, A: 0.75±0.18*#, AL: 1.39±0.20*$, AA: 1.42±0.22*$), TNF-α
(S: 0.63±0.10, B: 1.43±0.17*, A: 0.77±0.11*#, AL: 1.21±0.16*$, AA: 1.26±0.18*$). Inflammatory cells number (S: 137.2±26.4, B: 792.1±81.7*, A:
375.3±55.4*#, AL: 527.5±69.1*#$, AA: 516.3±71.4*#$). (*: P<0.01 vs. group S, #: P<0.01 vs. group B, $: P<0.01 vs. group A). All the measurements
were repeated for 3 times to figure out the arithmetic average. S=Sham operated group; B=Blank control group; A=Atorvastatin group;
AL=Atorvastatin+L-NAME group; AA=Atorvastatin+AMD3100 group.
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P < 0.05 was considered to be statistically significant.
Results
Expression of eNOS and p-eNOS in myocardium was
up-regulated by atorvastatin administration
As shown in Figure 1 (panel a), seven days after AMI,
comparing with group B, eNOS and p-eNOS were sig-
nificantly increased in all three atorvastatin therapy
groups (P<0.05) and the increment among these groups
were comparable, indicating that short term of atorvas-
tatin treatment had robust effects on eNOS and p-eNOS
upregulation.
Increases of NO production and SDF-1α expression in
myocardium by atorvastatin treatment
As shown in Figure 1 (panel b), one day after AMI, NO
production in all AMI groups were slightly increased
when compared with group S. Seven days later, NO
production in both group A and group A+AMD3100
was significantly increased (P<0.05, vs group B), while
the efficacy of atorvastatin on NO production was abro-
gated by L-NAME addition, as evidenced by the NO
production in group A+L-NAME was reduced. SDF-1α
concentration was concomitantly evaluated by ELISA.
As shown in Figure 1 (panel c), one day after AMI,
comparing with group S, SDF-1α expression in all AMI
groups were also slightly increased, consistent with pre-
vious report that SDF-1α could spontaneously increase
after ischemic insult. Seven days later, SDF-1α expression
in both group A and group A+AMD3100 was profoundly
up-regulated when compared with group A+L-NAME, in-
dicating that inhibition of NO production diminished
SDF-1α expression. Additionally, SDF-1α expression in
group B in day 7 was similar to that in day 1, indicating
that spontaneous upregulation of SDF-1α after ischemic
insult was a transient and temporal course.
Expression of STAT3 and CXCR4 in myocardium was
up-regulated by atorvastatin treatment
As shown in Figure 1 (panel d), seven days after AMI,
comparing with group B, CXCR4 and STAT3 expres-
sions were significantly increased in all three atorvastatintherapy groups (P<0.05). The expression of CXCR4 in
group A and group A+AMD3100 were significantly
higher than in group A+L-NAME, indicating that the
elevation of CXCR4 in cardiac tissues was also related to
eNOS/NO pathway. Although the expressions of CXCR4
and SDF-1α in group A and group A+AMD3100 were
comparable, the expression of STAT3 in group A
+AMD3100 was significantly lower than in group A,
supporting the notion that STAT3 expression was
mediated by CXCR4 and SDF-1α coupling.
Anti-inflammatory effects of atorvastatin
As shown in Figure 2 (panel a and b), seven days after
AMI, inflammatory reaction was mitigated in atorvasta-
tin treatment group when compared with group B. In-
hibition of NO production with L-NAME or blockage of
SDF-1α with CXCR4 coupling by AMD3100 could
potently offset the anti-inflammatory effects of atorvas-
tatin, as evidenced by the expression of inflammatory
cytokines and the number of inflammatory cells in group
A+L-NAME and group A+AMD3100 were higher than
in group A (P<0.05).
Anti-apoptotic effects of atorvastatin
Western blot and TUNEL were performed to evaluate
the anti-apoptotic effects of atorvastatin. As shown in
Figure 3 (panel a and b), both anti-apoptotic proteins
Bcl-2 and p-Akt were significantly up-regulated, ac-
companying with significant down-regulation of pro-
apoptotic protein Bax and reduction of apoptotic
index, in all three atorvastatin treated groups when
compared with group B. Compared with group A, the
effects of atorvastatin on anti-apoptosis in group A+L-
NAME and group A+AMD3100 were diminished,
indicating that upregulation of NO and SDF-1α, and
coupling of SDF-1α with CXCR4 were the underlying
mechanisms by which atorvastatin conferred anti-
apoptotic effects.
Cardiac function was improved by 7 day-atorvastatin
therapy
Parameters of cardiac function were listed in Table 1.
Briefly, one day after AMI, significant impairment of
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paring with group S. Enlargement of LVVs and LVVd in
all AMI groups also showed an acute dysfunction of left
ventricle. There was no statistical difference of cardiac
function among these four AMI groups on day 1 after
AMI. After 7 days of atorvastatin therapy, LVEF, FS
and CO were significantly improved, accompanying
with reduction of LVVs, LVVd and HR in group A,Figure 3 Panel (a) and (b), 7 days after AMI, Western blot analysis rev
proteins and reduced the pro-apoptotic protein, however, this effects w
1.13±0.15*, A: 1.56±0.22#, AL: 1.07±0.13*$, AA: 1.16±0.16*$) and p-Akt (S: 1.
and Bax (S: 0.10±0.02, B: 0.92±0.20*, A: 0.43±0.12*#, AL: 0.78±0.16*#$, AA: 0.
further suggested that the anti-apoptotic effects of atorvastatin was associa
coupling of SDF-1α with CXCR-4 (S: 6.94±2.12, B: 70.09±5.99*, A: 42.12±5.49
P<0.01 vs. group B, $: P<0.01 vs. group A). All the measurements were repe
operated group; B=Blank control group; A=Atorvastatin group; AL=Atorvasgroup A+L-NAME and group A+AMD3100 when
compared with group B. However, the improvement of
cardiac function was less prominent in group A+L-
NAME and group A+AMD3100 than in group A, indi-
cating that the protective effect on cardiac function
with atorvastatin treatment was associated with the
elevation of NO and SDF-1α, and the coupling of SDF-
1α with CXCR4.ealed that atorvastatin treatment increased the pro-survival
as diminished by either L-NAME or AMD3100. Bcl-2 (S: 1.51±0.24, B:
33±0.19, B: 0.87±0.16*, A: 1.36±0.20#, AL: 0.91±0.15*$, AA: 0.89±0.18*$),
76±0.13*#$). Apoptotic index of cardiomyocytes by TUNEL assay
ted with increase of NO production and SDF-1α expression, and the
*#, AL: 58.37±6.28*#$, AA: 55.72±7.31*#$). (*: P<0.01 vs. group S, #:
ated for 3 times to figure out the arithmetic average. S=Sham
tatin+L-NAME group; AA=Atorvastatin+AMD3100 group.
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Our present study showed that short term of atorvasta-
tin treatment could potently augment SDF-1α and
CXCR4 expression in ischemic cardiac tissue, which was
associated with the upregulation of eNOS/p-eNOS and
increase of NO. Furthermore, STAT3, which is a cardio-
protective factor, was also significantly increased through
SDF-1α and CXCR4 coupling. SDF-1α upregulation and
SDF-1α coupling with its cognate receptor CXCR4
contributed to the pleiotropic effects of atorvastatin
in terms of anti-inflammation and anti-apoptosis. Our
study presented a new insight into the roles and
mechanisms of atorvastatin treatment on SDF-1α
and CXCR4 expression, and upregulation of SDF-1α and
CXCR4 might be one of the mechanisms by which ator-
vastatin confer its pleiotropic effects. With regard to the
“off the shelf” advantage, we suggested that atorvastatin
might be a competent candidate used to immediately
up-regulate SDF-1α expression after urgent ischemic
insult, rather than intricately genetic approaches.
Statins are a class of medication which have been
broadly used in prevention and treatment of cardio-
vascular diseases. Other than the potent efficacy on
lipid profiles regulation, statins have pleiotropic effects























• * P<0.05 vs. Sham group.
• # P<0.05 vs. Blank Control group.
• $ P<0.05 vs. Atorvastatin group.
• S=Sham operated group; B=Blank control group; A=Atorvastatin group; AL=Atorvaapoptosis, stem cells mobilization and plaque stabili-
zation [17-20]. One of the important mechanisms
contributing to these pleiotropic effects is the stabili-
zation of eNOS mRNA and increase of eNOS expression
[15,21]. NO is generated by eNOS and modulates mul-
tiple processes contributing to improving cardiac func-
tion after ischemic insult [22,23]. Recently, one study
showed that eNOS over-expression in cardiac tissues by
genetic approach could up-regulate SDF-1α expression
[13]. However, whether SDF-1α could be up-regulated by
statins via eNOS/NO dependent pathway and whether
SDF-1α is the novel mechanism by which statins confer
its pleiotropic effects on cardiovascular diseases are still
unclear. In our present study, we showed that after seven
days of atorvastatin treatment, SDF-1α expression was
significantly increased in three atorvastatin treated
groups, accompanying with its specific receptor CXCR4.
But this efficacy was significantly abrogated when NO
production was diminished by L-NAME administration
in group A+L-NAME when compared with group A and
group A+AMD3100, indicating that SDF-1α and CXCR4
upregulation were largely attributed to NO production,
which, to our best knowledge, was the first time to reveal
that short term of atorvastatin treatment could signifi-
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pathway. However, the precise mechanism by which NO
up-regulate SDF-1α and CXCR4 expression is still un-
clear. In Feng’s study [13], they found that in the ische-
mic/reperfusion injury model, the increase of SDF-1α at
least partially via activation of soluble guanylyl cyclase
and increase of cGMP. In our study, the rats were under-
went permanent ligation of coronary artery which was
different from Feng’s study, and data from our pilot pro-
ject showed that neither adenlyly cyclase nor guanylyl
cyclase signaling pathway resulted in convincing results.
Therefore, the exact mechanism of SDF-1α up-regulation
remained inconclusive. Additionally, although NO produc-
tion in group A+L-NAME was abrogated at the seventh
day, the SDF-1α expression in group A+L-NAME was still
significantly higher than group B, indicating that SDF-1α
upregulation might also be ascribed to other mechanisms.
As it is well known that atorvastatin has anti-
inflammatory and anti-apoptotic effects. The mecha-
nisms are ascribed to the protective effects on endothelial
cells, production of NO, dilatation of vessel, activation of
pro-survival and inactivation of pro-apoptotic pathway.
And in Cui’s study [12], they revealed that simvastatin
treatment could up-regulate SDF-1α expression in ische-
mic brain which in turn to increase number of
transplanted stem cells to lesion area, and facilitate
neo-vascularization and improve the outcome. However,
the effects and mechanisms of SDF-1α coupling with
CXCR4 in ischemic brain tissues had not been intensively
investigated in Cui’s study. Literally, both SDF-1α and
CXCR4 simultaneously express in cardiac tissues, and the
beneficial effects of the pathway confers in ischemic car-
diac diseases have been intensively investigated, mostly
with genetic approach. In our present study, we revealed
that SDF-1α and CXCR4 expression, under the AMI set-
ting, could be up-regulated by short term of atorvastatin
treatment. Furthermore, the upregulation of SDF-1α and
CXCR4 could render robust anti-inflammatory and anti-
apoptotic effects via the coupling of SDF-1α with CXCR4,
as evidenced by that the efficacies were offset either when
AMD3100, the specific antagonist of CXCR4, was admini-
strated in group A+AMD3100, or the expressions of SDF-
1α and CXCR4 were reduced in group A+L-NAME.
Finally, our present study showed that the protective
effects on cardiac function by atorvastatin treatment was
associated with the upregulation of SDF-1α and the
coupling of SDF-1α with CXCR4, which was demon-
strated by cardiac function in terms of LVEF, FS and
CO, was significantly reduced when L-NAME or
AMD3100 was administrated. Moreover, since the ex-
pression of STAT3, a critical cardioprotective factor that
mediates SDF-1α/CXCR4 axis induced cardiac protection,
was up-regulated most significantly in group A than the
other groups, we considered that STAT3 upregulationowing to SDF-1α and CXCR4 coupling might partially re-
sponsible for cardiac function improvement.
Conclusion
With regard to the intensive advocates “from bench to
bedside” and “bridging basic research to clinical benefit”
nowadays, our present study for the first time identified a
new hint, which we consider to be a simple and clinically
feasible approach, to up-regulate SDF-1α expression by
commonly used medication statins rather than by pre-
viously complicated genetic approaches. Furthermore,
with regard to the effects on mobilization and engraftment
of stem cells by SDF-1α and CXCR4 axis, upregulation of
SDF-1α in ischemic cardiac tissues by statins therapy
could be a promising way in terms of myocardial regener-
ation in the future.
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